Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHL-301 in Adult Patients With Parkinson's Disease
NCT05931484Phase 2Withdrawn
- Sponsor
- Forest Hills Lab
- Start
- Nov 2027
- Primary completion
- Nov 2028
01
Overview
Phase 2, randomised, double-blind trial of gemfibrozil in Parkinson's disease (PD) (2 arms), sponsored by Forest Hills Lab. Primary endpoint: Unified Parkinson's Disease Rating Scale at 52 weeks. Planned start Nov 2027; status: withdrawn.
02
Drugs
gemfibrozil
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05931484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05931484.